載入中
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
前收盤價
US$88.15
−US$0.90 · -1.01%
盤中時間採用ET。市場資料可能有所延遲。
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
日內區間
目前US$88.15
52週區間
目前US$88.15
盤中時間採用ET。市場資料可能有所延遲。
Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.
日內區間
目前US$88.15
52週區間
目前US$88.15
營業利益
淨利
| 項目（EUR） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | — | — | — | 5076.4萬 EUR | 4551.7萬 EUR |
| 毛利 | — | — | — | −5076.4萬 EUR | −4551.7萬 EUR |
| 研究與開發 | 1.78億 EUR | 1.47億 EUR | 1.03億 EUR | 4829.5萬 EUR | 4778.1萬 EUR |
| 銷售、一般及管理費用 | 7286.5萬 EUR | 3890萬 EUR | 2882.2萬 EUR | 749.3萬 EUR | 557.9萬 EUR |
| 營業費用 | 2.46億 EUR | 1.73億 EUR | 1.27億 EUR | 1407.2萬 EUR | −411.7萬 EUR |
| 利息收入 | 575.3萬 EUR | 895.6萬 EUR | 277.3萬 EUR | — | — |
| 利息支出 | 2848.2萬 EUR | 1243.1萬 EUR | 1382.6萬 EUR | 694萬 EUR | 355.8萬 EUR |
| 折舊和攤銷 | 107.2萬 EUR | 110萬 EUR | 70.7萬 EUR | 48.5萬 EUR | 30.2萬 EUR |
| 營業利益 | −2.46億 EUR | −1.73億 EUR | −1.27億 EUR | −6483.6萬 EUR | −4140萬 EUR |
| 淨利 | −3.36億 EUR | −1.76億 EUR | −1.48億 EUR | −6074萬 EUR | −4245.2萬 EUR |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$156
上漲空間 76.97%報告持有此股票曝險的交易所交易基金。
iShares Biotechnology ETFIBB5015.22萬0.48%108.2億 USD0.44%US$206.49+3.00%
Schwab International Equity ETFSCHF1624.06萬0.02%674.08億 USD0.03%US$27.27+0.66%
Goldman Sachs Hedge Industry VIP ETFGVIP922.66萬1.59%5.79億 USD0.45%US$172.85+0.79%
State Street SPDR Portfolio Developed World ex-US ETFSPDW530.86萬0.01%404.62億 USD0.03%US$49.98+0.64%
Vanguard Total International Stock ETFVXUS316.37萬0.00%6657億 USD0.05%US$84.82+0.86%
Militia Long/Short Equity ETFORR289萬0.83%3.46億 USD10.91%US$38.52+1.02%
Vanguard FTSE Developed Markets ETFVEA210.48萬0.00%3238億 USD0.03%US$70.35+0.70%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM166.69萬0.24%6.94億 USD0.89%US$57.70+0.92%iShares Biotechnology ETFIBBSchwab International Equity ETFSCHFGoldman Sachs Hedge Industry VIP ETFGVIPState Street SPDR Portfolio Developed World ex-US ETFSPDWVanguard Total International Stock ETFVXUSMilitia Long/Short Equity ETFORRVanguard FTSE Developed Markets ETFVEAMorgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
